Insurance companies will now claim that Amarin is acting against patients' health...Amarin must counter this claim by saying their goal is to make Vascepa more affordable for more patients' CVD...and, by lowering Insurance companies' price tiers for Vascepa, Amarin is making Vascepa more affordable for more patients.